Latest MD Buyline Ratings Show Significant, Sustained Increase in User Satisfaction for Accuray Incorporated's TomoTherapy® System

SUNNYVALE, Calif., Feb. 11, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that overall user satisfaction for its TomoTherapy^® System has increased for the fifth consecutive quarter, according to the Q4 2013 MD Buyline Market Intelligence Briefing™. In addition, the latest report illustrates Accuray has exceeded market average for user satisfaction among linear accelerator vendors for the second consecutive quarter.

MD Buyline, an independent market intelligence organization for the healthcare industry, measures linear accelerator user satisfaction based on evaluations by more than 3,300 hospitals. Respondents rate how satisfied they are with products from Accuray, Elekta and Varian, using key metrics such as system performance, system reliability and service response time.

In rating the TomoTherapy System, MD Buyline noted, "Customers are pleased with TomoTherapy, citing the system surpasses their expectations. Users are pleased with the recent improvements in treatment planning and the ability to treat using dynamic jaws."

"The steady increase in satisfaction ratings validates our approach to ensuring optimal performance of the TomoTherapy System," said Joshua H. Levine, president and chief executive officer of Accuray. "Our customers are realizing the benefits of new capabilities, redesigned components and award-winning service."

About Accuray

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to customer satisfaction, system performance, product updates and service quality. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from under the heading "Risk Factors" in Accuray's report on Form 10-K which was filed on August 29,2013, and the company's report on Form 10-Q, which was filed on November 8, 2013.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

SOURCE Accuray Incorporated